http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA03010731-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate | 2002-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfcba0e0b6afe094d490042738a4e38e |
| publicationDate | 2004-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-PA03010731-A |
| titleOfInvention | COMBINATION OF ADENOSINE AND TIOTROPY A2A RECEIVER AGONIST OR ITS DERIVATIVES TO TREAT OBSTRUCTIVE AIRWAY DISEASES. |
| abstract | A combination of therapeutic agents useful in the treatment of obstructive airway diseases and other inflammatory diseases, comprising: (i) an adenosine A2A receptor agonist; and (ii) an anticholinergic agent, preferably comprising a member selected from the group consisting of tiotropium and its derivatives; the combination being therapeutically effective in the treatment of diseases when administered by inhalation; as well as a method to treat obstructive diseases of the airways and other inflammatory diseases comprising administering by inhalation to the mammal, separately, simultaneously or sequentially, a therapeutically effective amount of the combination of therapeutic agents; as well as a pharmaceutical composition comprising a pharmaceutically acceptable vehicle together with the combination of therapeutic agents; as well as a product that contains the compounds of the combination for administration by inhalation, separately, simultaneously or sequentially, to a mammal for the treatment of obstructive diseases of the airways and other inflammatory diseases. It is preferred that the anticholinergic agent component be tiotropium bromide. |
| priorityDate | 2001-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.